For laboratory and educational research use only. Not medical advice.
Women's Peptide Research
Ask Vera
Home  /  Database  /  Liraglutide
Weight & Metabolicapproved

Liraglutide

Victoza
Weight & Metabolic
ASK VERA ABOUT THIS ↗BROWSE THE CATALOG ↗
Category
Weight & Metabolic
Evidence grade
A
PubMed records
5,517
Female-tagged
1,339
Sex-analysis
18
CAS
—
A
Evidence grade A, Approved indication with 1339 indexed studies that included female subjects. How grades work →
Female evidence: Direct
Liraglutide: of 5,517 PubMed records, 1,339 are tagged as including female subjects and 18 carry a sex-analysis tag.Counts reflect PubMed records as of 2026-07-17. “Female” uses the Female MeSH filter and “sex-analysis” the Sex Factors MeSH filter, automated proxies pending manual study-level review. Methodology →

Overview

Liraglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that has been approved as Victoza for type 2 diabetes and as Saxenda for chronic weight management. Structurally it is a modified analogue of native GLP-1 carrying a fatty-acid chain that extends its half-life, allowing once-daily administration and giving it a well-characterized pharmacological profile.

At the receptor level, liraglutide has been studied for its enhancement of glucose-dependent insulin secretion, its slowing of gastric emptying, and its influence on satiety signaling. Because its registration trials enrolled large numbers of participants, its overall evidence base is far broader than most compounds cataloged here, and it has been investigated extensively in metabolic and incretin-pathway research.

As an approved and heavily studied GLP-1 agonist, liraglutide is a useful reference point in a metabolic catalog. Its trials included many women, though cycle-specific questions were rarely pre-specified; our evidence review tracks how many of the underlying studies reported outcomes by sex.

Summary

Liraglutide is a GLP-1 receptor agonist approved as Victoza (type 2 diabetes) and Saxenda (chronic weight management). Its registration trials enrolled large numbers of women, so, like other approved GLP-1 agonists, its overall evidence base is far stronger than most compounds here, even though cycle-specific questions were rarely pre-specified.

Evidence in women

Menstrual cycle
Unstudied
Menstrual cycle-phase effects were not a pre-specified analysis in the registration trials, despite appetite and gastric emptying varying across the cycle.
Pregnancy & lactation
Contraindicated
Weight-management use is not recommended in pregnancy; discontinue when pregnancy is recognized. Lactation effects are not established.
Hormonal interactions
No evidence
Unlike tirzepatide, liraglutide's labeling reports no clinically significant effect on oral-contraceptive pharmacokinetics, a documented absence of interaction rather than an untested one.
Perimenopause & menopause
No evidence
Efficacy and safety in postmenopausal women were not established as a separate analysis.
Sex differences
Evidence
Trials enrolled large numbers of women and demonstrated effects in female participants; formal sex-stratified analyses are limited.

Mechanism

GLP-1 receptor agonist: enhances glucose-dependent insulin secretion, slows gastric emptying, and increases satiety. Administered once daily (shorter-acting than semaglutide).

Reported dosing & routes

◐

We don't give dosing or medical advice. The figures below describe what was used in published research, not a recommendation. Decide with your clinician.

Reported range (literature)Approved labels use titrated subcutaneous daily dosing (literature figures, not advice).
Routessubcutaneous
Female-specific dosingNot established

Contraindications: personal or family history of medullary thyroid carcinoma or MEN 2 (label boxed warning); pregnancy (weight-management use)

Side effects

Reported in the research literature. Sex-specific incidence has not been separately analysed in the available records.

nauseavomitingdiarrheainjection-site reactionsgallbladder events

Liraglutide reconstitution calculator

Enter this vial's amount, the bacteriostatic water you add, and a target amount to get the concentration and the U-100 syringe units to draw. Handling arithmetic for research use, not a dose recommendation.

Reconstitution

1
2
3

Draw for Liraglutide

5
units on a U-100 insulin syringe
020406080100
U-100 insulin syringe — 1 mL = 100 units
That's 0.05 mL drawn to the 5-unit mark.
Concentration5 mg/mL (5,000 mcg/mL)
Volume to draw0.05 mL
Doses per vial40

Reference chart at 5 mg/mL

Target amountVolume (mL)U-100 units
100 mcg0.02 mL2
250 mcg0.05 mL5
500 mcg0.1 mL10
750 mcg0.15 mL15
1000 mcg0.2 mL20

Research-use arithmetic only. This tool converts a vial amount, diluent volume, and a target amount into a concentration and syringe draw for laboratory handling. It is not dosing guidance, a recommendation, or a claim of safety or efficacy, and it does not account for overfill, dead space, or peptide purity. Nothing here is medical advice. “U-100” means 100 units = 1 mL; confirm your syringe graduation before measuring. See the reconstitution & storage handbook for handling detail.

Frequently asked questions

Answers drawn only from Liraglutide's research facts and, where reviewed, its sex-disaggregated evidence. Nothing here is medical advice, dosing, or a claim of safety or efficacy.

What is Liraglutide?

Liraglutide, also known as Victoza, is a research compound in our weight metabolic category. Liraglutide is a GLP-1 receptor agonist approved as Victoza (type 2 diabetes) and Saxenda (chronic weight management).

Is Liraglutide studied in women?

Liraglutide: of 5,517 PubMed records, 1,339 are tagged as including female subjects and 18 carry a sex-analysis tag. We grade this direct female evidence: at least one record carries a sex-analysis tag, so some findings are drawn from women rather than borrowed from mixed or male data. See how we read the evidence.

Has Liraglutide been studied during pregnancy or breastfeeding?

Contraindicated. Weight-management use is not recommended in pregnancy; discontinue when pregnancy is recognized. Lactation effects are not established. This is not a safety clearance or a recommendation. Vera, our research chat, deliberately hard-stops on pregnancy, breastfeeding, and trying-to-conceive questions rather than answer them.

What evidence grade does Liraglutide have, and why?

Liraglutide carries evidence grade A. Approved indication with 1339 indexed studies that included female subjects.. Grades are derived from the research record, never hand-assigned; see how grades work.

Is there a female-specific dose for Liraglutide?

No. A female-specific dose for Liraglutide is not established, and this site does not provide dosing or medical advice. Any figures we show describe what published research used, not a recommendation. Decide anything about use with a qualified clinician.

How is Liraglutide administered in research?

In the published literature, Liraglutide is administered via subcutaneous. Reported dose ranges on the Dosing tab describe what studies used for laboratory research, not a protocol for people. We don't provide dosing.

What side effects have been reported for Liraglutide?

Effects reported in the research literature include nausea, vomiting, diarrhea, injection-site reactions, gallbladder events. Sex-specific incidence has not been separately analysed in the available records, so these are not broken out for women.

How should Liraglutide be stored and handled?

Liraglutide sold for research is supplied as a lyophilized (freeze-dried) powder. Lyophilized peptides are generally kept cold and dry, at roughly -20°C for longer-term storage and 2-8°C short-term, protected from light. Once reconstituted they are typically refrigerated and used within a short window, avoiding repeated freeze-thaw cycles. This is general laboratory handling for research use only, not a directive for human use. Always follow the handling and purity details on the product's Certificate of Analysis.

Where can I buy Liraglutide for research?

Liraglutide is not currently listed by our research-use partner, Aurevena Research, but their catalog carries related compounds. Code research15 applies 15% off. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.

Browse the Aurevena catalog
Research-use supplier: Liraglutide isn't currently listed by our research-use vendor. Their catalog carries related compounds. Code research15 for 15% off, applied automatically at checkout. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.
Browse the catalog →

Related peptides

4X Blend (Methionine / Choline / Carnitine / Dexpanthenol)·
Multi-ingredient blend, its female evidence is reviewed per ingredient, not for the combination.
5-Amino-1MQD
5-Amino-1MQ: of 3 PubMed records, 2 are tagged as including female subjects and 0 carry a sex-analysis tag.
8X Blend (L-Carnitine / L-Arginine / Methionine / Inositol / Choline / B6 / B5 / B12)·
Multi-ingredient blend, its female evidence is reviewed per ingredient, not for the combination.
AdipotideD
Adipotide: of 4 PubMed records, 2 are tagged as including female subjects and 0 carry a sex-analysis tag.

Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe.